1st Circuit Affirms Dismissal Of All But 1 Fabrazyme Shortage Claim

(June 1, 2016, 7:00 AM EDT) -- BOSTON — The First Circuit U.S. Court of Appeals on May 23 said only one plaintiff in two class actions pleaded an injury claim from a shortage of the drug Fabrazyme while the others failed to do so (Anita Hochendoner, et al. v. Genzyme Corporation, No. 15-1446, Philip Adamo, et al. v. Genzyme Corporation, No. 15-1447, 1st Cir.; 2016 U.S. App. LEXIS 9438).

(Opinion in Section A. Document #28-160602-003Z.)

Patients suffering from Fabry disease sued Genzyme Corp. in the U.S. District Court for the District of...
To view the full article, register now.